Shop / Retatrutide
Retatrutide
Triple agonist — investigational, not for sale
Retatrutide is a triple agonist — GIP, GLP-1 and glucagon. On the Phase 2 results it is the most effective weight-loss drug published to date.
It is also investigational. It is not FDA-approved, it is not on any compounding list, and there is no lawful way to obtain it outside a clinical trial. Sites selling it today are selling it as a research chemical labelled not for human consumption, which is the only way it can be sold at all.
Lilly has said it intends to file in the first quarter of 2027. If it is approved we will add it, on the approved label, and this page will change.
Human data exists, but it is older, smaller or narrower than the claims commonly made about this compound.
Mean body-weight change at 48 weeks on the highest dose in Phase 2
Jastreboff · NEJM 2023Adults randomised — a Phase 2 trial, not a Phase 3 programme
Jastreboff · NEJM 2023Legal routes to obtain it outside a clinical trial
As of August 2026What it is
Retatrutide is a triple agonist — GIP, GLP-1 and glucagon receptors — and on the Phase 2 numbers it is the most effective weight-loss drug anyone has published. It is also investigational. It is not approved by the FDA, not on any compounding list, and Whealth does not and cannot sell it. Nobody legally can.
How it works
The GIP and GLP-1 halves do what tirzepatide does. The third arm, glucagon, raises energy expenditure rather than only reducing intake — which is the mechanistic reason the numbers are larger, and also why the cardiovascular and hepatic safety picture needs a full Phase 3 before anyone should be taking it casually.
What the evidence actually says
-
2023
Phase 2
338 adults with obesity. Mean −24.2% body weight at 48 weeks on the top dose — the largest figure published for any obesity drug, and the reason you have heard of it.
-
2026
Phase 3 running
The TRIUMPH programme, Lilly's largest obesity study, with more than 5,800 participants. Still enrolling and reporting.
-
2027
Earliest filing
Lilly has said it intends to submit to the FDA in the first quarter of 2027. Review typically runs 10–12 months, which puts a decision in late 2027 or 2028 at the earliest.
What the first months look like
- TodayNothing, from us or from any legitimate pharmacy. The only lawful access is enrolment in a trial.
- If approvedWe would add it, at the approved dose, on the approved label — and this page would change to say so.
Who this is not for
- Anyone, from us, at present.
- If you are buying it elsewhere: an unapproved drug has no manufacturer, no established dose for you, and no recall route. Sterility and identity are whatever the seller says they are.
How to actually get this
There is one lawful route to an investigational drug and it is a clinical trial. These were recruiting when this page was written. Enrolment is free, the medicine is supervised, and you may receive placebo — that last part is the point of the exercise, not a catch.
NCT07467447 Retatrutide versus placebo in adults with obesity or overweight. Phase 2 · obesity or overweight · 300 participants NCT07165028 A master protocol of multiple agents in adults with metabolic dysfunction-associated steatotic liver disease. Phase 3 · MASLD · 4,500 participants · Eli LillyWe are not affiliated with these studies and we are not paid to list them. Take the identifier to your own physician.
Sources
Figures are quoted from the published trials and were last checked in August 2026. We update this page when the evidence changes.